Statement of Organization, Functions, and Delegations of Authority, 57455-57457 [2017-26150]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 232 / Tuesday, December 5, 2017 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
sradovich on DSK3GMQ082PROD with NOTICES
Statement of Organization, Functions,
and Delegations of Authority
Part C (Centers for Disease Control
and Prevention) of the Statement of
Organization, Functions, and
Delegations of Authority of the
Department of Health and Human
Services (45 FR 67772–76, dated
October 14, 1980, and corrected at 45 FR
69296, October 20, 1980, as amended
most recently at 81 FR 84583–84591,
dated November 23, 2016) is amended
to reflect the reorganization of the
Division of Viral Diseases, National
Center for Immunization and
Respiratory Diseases, Office of
Infectious Disease, Centers for Disease
Control and Prevention.
Section C–B, Organization and
Functions, is hereby amended as
follows:
Delete and replace the title and the
mission and function statements for the
Division of Viral Disease (CVGE) and
insert the following:
Division of Viral Disease (CVGE). The
Division of Viral Diseases (DVD)
prevents disease, disability, and death
through immunization and by control of
respiratory, enteric, and related viral
diseases. In carrying out this mission,
the DVD: (1) Conducts surveillance and
related activities; supports and provides
technical assistance to state and local
health departments to conduct
surveillance and related activities to
monitor the impact of vaccination and
other prevention programs; and
determine patterns of infection and
disease; (2) conducts epidemiologic and
laboratory studies to define patterns of,
and risk factors for, infection, disease,
and disease burden; estimates vaccine
effectiveness, determines cost
effectiveness of vaccines, and evaluates
other aspects of immunization practices;
identifies and evaluates non-vaccine
prevention strategies; and provides
epidemiological and laboratory
expertise to other Nation Centers (NCs),
collaborators, and partners on vaccine
and other prevention strategies; (3)
provides consultation on viral vaccine
preventable, respiratory, and enteric
diseases, and the use of vaccines and
other measures to prevent infections; (4)
provides consultation and support and/
or participates in investigations of
national and international outbreaks of
viral vaccine preventable and other
respiratory and enteric viral diseases,
and recommends appropriate control
VerDate Sep<11>2014
18:13 Dec 04, 2017
Jkt 244001
measures; (5) provides scientific
leadership and advice, analyzes
available data, and develops sciencebased statements for viral vaccines to
the Advisory Committee on
Immunization Practices (ACIP) and
other groups to support the
development and evaluation of
immunization practices and policies
domestically and internationally; (6)
provides laboratory support for
surveillance and epidemiologic studies
and maintains reference/diagnostic
services and expertise; (7) conducts
studies of immunology and
pathogenesis of disease and the biology,
biochemical, genetic and antigenic
characteristics of the agents; (8)
develops, evaluates, and improves
diagnostic methods and reagents, and
transfers assays and techniques to other
public health laboratories; (9) facilitates
and participates in the development and
evaluation of antiviral compounds,
vaccines, and vaccination programs;
(10) provides and supports public
health training; (11) responds to and
assists internal and external partners on
other public health problems of national
and international significance, as
needed; (12) provides technical support
to state immunization programs for all
aspects of vaccine-preventable diseases
and their vaccines; (13) provides
leadership in vaccine science; and (14)
supports CDC’s Immunization Safety
Office in vaccine safety risk assessment
and leadership in vaccine safety risk
management.
Office of the Director (CVGE1). (1)
Manages, directs, and coordinates the
activities of the division; (2) provides
leadership and guidance in policy
formulation, program planning and
development, program management,
and operations of the division; (3)
identifies needs and resources for
ongoing and new initiatives and assigns
responsibilities for their development;
(4) prepares, reviews, and coordinates
informational, scientific, and
programmatic documents; (5) oversees
the division’s activities and
expenditures; (6) assures the overall
quality of the science conducted by the
division; (7) provides overall guidance
and direction for the division’s
surveillance, research, and other
scientific and immunization activities;
(8) provides overall guidance and
direction for division’s epidemiologic,
laboratory, and outbreak response
capacity and activities; (9) oversees and
facilitates the division’s scientific
support to other groups within CDC, the
national and international healthcare,
and public health communities
regarding viral respiratory and enteric
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
57455
diseases and viral immunization
programs; (10) guides and facilitates
efficient coordination and cooperation
for administrative, programmatic, and
scientific activities within the division
and with other groups inside and
outside of CDC; and (11) provides
division leadership, expertise, and
technical collaboration for the
application of statistics, economics,
operations research, geography, other
quantitative sciences, and data
management to prevent disease,
disability and death through
immunization and control of
respiratory, enteric, and related viral
diseases.
Analysis and Data Management
Activity (CVGE12). (1) Coordinates
quantitative science and data
management planning, policy
development, and project monitoring
and evaluation; (2) designs and
develops statistical, economic, cost,
resource allocation, geospatial and data
management strategies, models, and
methodologies in the public health
arena; and (3) collaborates with
scientists, program experts, and senior
public health officials throughout the
division to implement these strategies,
models, and methodologies in support
of respiratory, enteric and related viral
diseases surveillance and prevention
studies, prevention resource allocation
issues, and prevention program
activities.
Respiratory Viruses Branch (CVGEB).
(1) Conducts surveillance, laboratory
assistance, and related activities, and
supports and provides technical
assistance to state and local health
departments to conduct surveillance
and related activities to monitor the
impact of prevention programs, and
determine patterns of infection and
disease; (2) conducts and provides
laboratory support and expertise for
epidemiologic and laboratory studies to
define patterns of and risk factors for
infection, disease, and disease burden;
(3) provides epidemiology and
laboratory consultation and support
and/or participates in investigations of
national and international outbreaks of
viral respiratory diseases, and
recommends appropriate control
measures; (4) provides scientific, both
epidemiologic and laboratory,
leadership and advice; (5) analyzes
available data, and develops sciencebased statements for potential
respiratory viral vaccines to the ACIP
and other groups to support the
development and evaluation of
immunization practices and policies in
the U.S and internationally; (6) provides
and supports public health training; (7)
responds to and assists internal and
E:\FR\FM\05DEN1.SGM
05DEN1
sradovich on DSK3GMQ082PROD with NOTICES
57456
Federal Register / Vol. 82, No. 232 / Tuesday, December 5, 2017 / Notices
external partners on other public health
problems of national and international
significance, as needed; (8) provides
laboratory support for surveillance and
epidemiologic studies and maintains
reference/diagnostic services and
expertise; (9) conducts studies of
immunology and pathogenesis of
disease and the biology, biochemical,
genetic, and antigenic characteristics of
the agents; (10) develops, evaluates, and
improves diagnostic methods and
reagents, and transfers assays and
techniques to other public health
laboratories and provides and supports
laboratory training; (11) facilitates and
participates in the development and
evaluation of antiviral compounds,
vaccines, and vaccination programs; and
(12) responds to and assists internal and
external partners on other public health
problems of national and international
significance as needed.
Polio and Picornavirus Laboratory
Branch (CVGEC). (1) Provides laboratory
assistance, technical expertise and
support for surveillance and related
activities to monitor impact of
vaccination and other prevention
programs, and determine patterns of
infection and disease; (2) provides
laboratory support and technical
expertise for epidemiologic and
laboratory studies to define patterns and
risk factors for infection, disease, and
disease burden; (3) studies vaccinerelated issues; (4) identifies and
evaluate non-vaccine prevention
strategies; (5) provides laboratory
consultation and technical expertise
regarding use of vaccines and other
measures to prevent infections to other
NCs, collaborators, and partners; (6)
provides laboratory consultation and
support and/or participates in
investigations of national and
international outbreaks of viral vaccine
preventable and other respiratory and
enteric viral diseases; (7) provides
laboratory leadership and technical
expertise to develop science-based
statements to Global Polio Eradication
Initiative, the ACIP, and other groups to
support the development and evaluation
of immunization practices and policies
in the U.S and internationally; (8)
provides epidemiology and laboratory
consultation and support and/or
participates in investigations of national
and international outbreaks of viral
respiratory diseases, and recommends
appropriate control measures; (9)
provides scientific, both epidemiologic
and laboratory, leadership and advice;
(10) provides laboratory support for
surveillance and epidemiologic studies
and maintains reference/diagnostic
services and expertise; (11) conducts
VerDate Sep<11>2014
18:13 Dec 04, 2017
Jkt 244001
studies of immunology and
pathogenesis of disease and the biology,
biochemical, genetic, and antigenic
characteristics of the agents; (12)
develops, evaluates, and improves
diagnostic methods and reagents,
transfers assays and techniques to
national and international public health
laboratories, and provides and supports
training for laboratorians; (13) facilitates
and participates in the development and
evaluation of antiviral compounds,
vaccines, and vaccination programs;
(14) responds to and assists internal and
external partners on other public health
problems of national and international
significance as needed; and (15) serves
as the National Reference Laboratory
(poliovirus and enteroviruses), World
Health Organization (WHO)
Collaborating Center for Poliovirus and
Enteroviruses Virus Reference and
Research, and WHO Global Specialized
Polio Reference Laboratory.
Viral Vaccine Preventable Diseases
Branch (CVGED). (1) Conducts
surveillance, provides laboratory
assistance, technical expertise, and
support for surveillance and related
activities to monitor the impact of
vaccination on the prevention of viral
disease and to determine patterns of
infection and disease; (2) conducts
epidemiologic and laboratory studies to
define patterns of and risk factors for
infection, disease, and disease burden;
(3) estimates vaccine effectiveness,
evaluates other aspects of immunization
practices; (4) identifies and evaluates
non-vaccine prevention strategies; (5)
provides epidemiological and laboratory
expertise and technical support to other
NCs, collaborators, and partners across
center working groups on vaccines and
other prevention strategies; (6) supports
the development of vaccine practices
and policies by providing consultation
and epidemiologic and laboratory
expertise to other federal agencies, state
health departments, ministries of health,
WHO, PAHO, private industry,
academia and other governmental
organizations on viral vaccine
preventable diseases, and on the use of
vaccines and other measures to prevent
infections; (7) provides laboratory
consultation and support and/or
participates in investigations of national
and international outbreaks of viral
vaccine preventable diseases and
recommends appropriate control
measures; (8) assists internal and
external partners on other public health
problems of national and international
significance; (9) provides scientific
leadership and advice, analyzes
available data, and develops sciencebased statements for viral vaccines to
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
the ACIP and other groups to support
the development and evaluation of
immunization practices and policies in
the U.S and internationally; (10)
responsible for human papilloma virus
(HPV), measles, mumps, rubella (MMR),
domestic polio, zoster, and varicella
vaccine policy in the United States by
working with ACIP; (11) provides and
supports public health training; (12)
responds to public inquires and
prepares communication materials; (13)
works with health economists to
determine cost effectiveness of
vaccination strategies; (14) provides
laboratory support for surveillance and
epidemiologic studies and maintains
reference and diagnostic services and
expertise; (15) assists in investigation of
adverse events following vaccination;
(16) conducts studies of immunology
and pathogenesis of disease and the
biological, biochemical, genetic, and
antigenic characteristics of viral agents;
(17) develops, evaluates, and improves
diagnostic methods and reagents; (17)
transfers assays and techniques to other
public health laboratories; (18) provides
and supports laboratory training; (19)
serves as the National Reference
Laboratory for MMR, and varicella
zoster virus and the PAHO Regional and
WHO Global Specialized Laboratory for
measles and rubella; and (20) works
closely with the laboratory that handles
HPV to define and conduct
epidemiologic investigations.
Viral Gastroenteritis Branch (CVGEE)
(1) Provides epidemiologic and
laboratory assistance studies and related
activities to better understand the
evolution, (molecular) epidemiology
and immunity of rotavirus, norovirus
and other gastroenteritis viruses; (2)
provides consultation on the safety and
impact of rotavirus vaccination and
other prevention programs (rotavirus,
norovirus); (3) provides consultation
and technical assistance to state and
local health departments to monitor the
burden of disease and epidemiology of
gastroenteritis virus infections
(rotavirus, norovirus); (4) provides
consultation and support on the
research and development of new
rotavirus vaccines and other prevention
technologies; (5) provides consultation
and support and/or participates in
investigations of national and
international outbreaks of viral vaccine
preventable and other enteric viral
diseases, and recommends appropriate
control measures; (6) provides scientific
leadership and advice, analyzes
available data, and develops sciencebased statements for rotavirus vaccines
to the ACIP and other groups to support
the development and evaluation of
E:\FR\FM\05DEN1.SGM
05DEN1
Federal Register / Vol. 82, No. 232 / Tuesday, December 5, 2017 / Notices
immunization practices and policies in
the U.S and internationally; (7) provides
and supports public health training; (8)
responds to and assists internal and
external partners on other public health
problems of national and international
significance, as needed; (9) serves as the
National Reference Laboratory (rotavirus
and norovirus) and other agents of viral
gastroenteritis; and (10) serves as the
WHO Global Reference Center for
Rotavirus and other agents of viral
gastroenteritis.
Sherri Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2017–26150 Filed 12–4–17; 8:45 am]
BILLING CODE 4160–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
sradovich on DSK3GMQ082PROD with NOTICES
Statement of Organization, Functions,
and Delegations of Authority
Part C (Centers for Disease Control
and Prevention) of the Statement of
Organization, Functions, and
Delegations of Authority of the
Department of Health and Human
Services (45 FR 67772–76, dated
October 14, 1980, and corrected at 45 FR
69296, October 20, 1980, as amended
most recently at 81 FR 84583–84591,
dated November 23, 2016) is amended
to reflect the reorganization of the
Center for Surveillance, Epidemiology
and Laboratory Services, Office of
Public Health Preparedness and
Response, Centers for Disease Control
and Prevention.
Section C–B, Organization and
Functions, is hereby amended as
follows:
Delete in its entirety the title for the
Center for Surveillance, Epidemiology
and Laboratory Service (CPN) and insert
the following title which includes the
Oxford comma: Center for Surveillance,
Epidemiology, and Laboratory Service
(CPN).
Delete in its entirety the title and the
mission and function statements for the
Division of Laboratory Systems (CPNB)
and insert the following:
Division of Laboratory Systems
(CPNB). The mission of the Division of
Laboratory Systems (DLS) is to
strengthen the nation’s clinical and
public health laboratory system by
continually improving quality and
safety, informatics and data science, and
workforce competency.
Office of the Director (CPNB1). (1)
Provides leadership and guidance on
VerDate Sep<11>2014
18:13 Dec 04, 2017
Jkt 244001
development of strategic goals,
objectives, and milestones to advance
the vision and mission of the Division
of Laboratory Systems (DLS), the Center
for Surveillance Epidemiology and
Laboratory Services (CSELS), and CDC;
(2) ensures optimal planning and
allocation of resources to achieve
program objectives, conducts
management and operations analyses,
and oversees required reporting; (3)
provides administrative management
support, advice, and guidance to DLS
regarding administrative policies, fiscal
management, property management,
human resources, and travel; (4) leads
coordination and stewardship of DLS
procurement, grants, cooperative
agreements, materials management,
interagency agreements, and extramural
resources; (5) fosters collaborations and
cross-cutting activities with other CDC
components and external organizations
to support the mission, activities, and
operations of DLS; (6) enhances internal
and external partnerships and partner/
stakeholder communication; (7)
provides leadership in evaluating and
improving program performance,
monitoring progress and
accomplishments to ensure that
programmatic goals are achieved with
measurable impact; (8) manages issues,
policy development, and tracks
regulatory and legislative activities; (9)
manages CDC Specimen Policy Board
and the CDC/ATSDR Specimen
Packaging, Inventory, and Repository
(CASPIR) Advisory Committee; (10)
collaborates with leadership of the
Centers for Medicare & Medicaid
Services (CMS) and the Food and Drug
Administration (FDA) in advancement
of the Clinical Laboratory Improvement
Amendments (CLIA) program and
oversees CDC responsibilities therein;
(11) provides scientific oversight for
DLS, performing scientific review and
clearance for DLS publications,
presentations, and reports; (12) provides
DLS communications, Web support,
responses to media requests, and
communication outreach efforts; and
(13) coordinates requests from other
CDC programs for international
technical assistance among DLS
capabilities.
Training and Workforce Development
Branch (CPNBC). (1) Provides
leadership and support of laboratory
workforce through initiatives that
strengthen recruitment, retention,
management, and training; (2) supports
the development, promotion, adoption,
and implementation of competencies
relevant to the laboratory workforce; (3)
develops frameworks, models, and
resources that support competency-
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
57457
based laboratory training, fellowships,
and education; (4) engages agency and
laboratory community experts to
collaboratively assess and develop
effective training products to maintain a
competent, prepared, and sustainable
national and global laboratory
workforce; (5) designs and implements
training pertaining to clinical and
public health laboratory methodology,
technology, quality and safety and
practice for public health, clinical, CDC,
and other federal agency laboratory
professionals; and (6) evaluates the
efficiency and effectiveness of public
health laboratory education and
training, including measuring the
outcomes of all training to ensure the
effective transfer of knowledge and
skills to improved laboratory practice.
Quality and Safety Systems Branch
(CPNBD). (1) Develops, promotes,
implements, and evaluates intervention
strategies to improve quality and safety
in clinical and public health laboratory
systems; (2) provides scientific and
technical support for the Clinical
Laboratory Improvement Amendments
(CLIA) program to assure the quality,
including safety, of clinical and public
health laboratory testing nationwide; (3)
facilitates and conducts studies to
provide scientific evidence and assess
the impact of CLIA regulations and
voluntary guidelines for laboratory
quality and safety; (4) provides expertise
and guidance in the development or
revision of CLIA technical standards
and voluntary guidelines for laboratory
quality and safety, especially in light of
new and evolving laboratory technology
and practices; (5) develops,
disseminates, promotes, and evaluates
the impact of educational materials to
support the understanding of and
compliance with CLIA regulations and
voluntary quality and safety guidelines;
(6) hosts and manages the Clinical
Laboratory Improvement Advisory
Committee (CLIAC) and its workgroups
on behalf of a tri-agency partnership
among CDC, CMS, and FDA; (7)
provides information to the laboratory
medicine and public health
communities, as well as policy makers,
regarding the interpretation and
application of the CLIA technical
standards and other issues of laboratory
quality and safety; (8) provides
technical assistance in the review of
laboratory accreditation and state
licensure programs, and CLIA-approved
proficiency testing programs; (9)
facilitates and supports collaborations
with federal partners and other
stakeholders (including other CDC
programs upon request) for the
exchange of information about
E:\FR\FM\05DEN1.SGM
05DEN1
]]>Agencies
[Federal Register Volume 82, Number 232 (Tuesday, December 5, 2017)]
[Notices]
[Pages 57455-57457]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-26150]
[[Page 57455]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Statement of Organization, Functions, and Delegations of
Authority
Part C (Centers for Disease Control and Prevention) of the
Statement of Organization, Functions, and Delegations of Authority of
the Department of Health and Human Services (45 FR 67772-76, dated
October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as
amended most recently at 81 FR 84583-84591, dated November 23, 2016) is
amended to reflect the reorganization of the Division of Viral
Diseases, National Center for Immunization and Respiratory Diseases,
Office of Infectious Disease, Centers for Disease Control and
Prevention.
Section C-B, Organization and Functions, is hereby amended as
follows:
Delete and replace the title and the mission and function
statements for the Division of Viral Disease (CVGE) and insert the
following:
Division of Viral Disease (CVGE). The Division of Viral Diseases
(DVD) prevents disease, disability, and death through immunization and
by control of respiratory, enteric, and related viral diseases. In
carrying out this mission, the DVD: (1) Conducts surveillance and
related activities; supports and provides technical assistance to state
and local health departments to conduct surveillance and related
activities to monitor the impact of vaccination and other prevention
programs; and determine patterns of infection and disease; (2) conducts
epidemiologic and laboratory studies to define patterns of, and risk
factors for, infection, disease, and disease burden; estimates vaccine
effectiveness, determines cost effectiveness of vaccines, and evaluates
other aspects of immunization practices; identifies and evaluates non-
vaccine prevention strategies; and provides epidemiological and
laboratory expertise to other Nation Centers (NCs), collaborators, and
partners on vaccine and other prevention strategies; (3) provides
consultation on viral vaccine preventable, respiratory, and enteric
diseases, and the use of vaccines and other measures to prevent
infections; (4) provides consultation and support and/or participates
in investigations of national and international outbreaks of viral
vaccine preventable and other respiratory and enteric viral diseases,
and recommends appropriate control measures; (5) provides scientific
leadership and advice, analyzes available data, and develops science-
based statements for viral vaccines to the Advisory Committee on
Immunization Practices (ACIP) and other groups to support the
development and evaluation of immunization practices and policies
domestically and internationally; (6) provides laboratory support for
surveillance and epidemiologic studies and maintains reference/
diagnostic services and expertise; (7) conducts studies of immunology
and pathogenesis of disease and the biology, biochemical, genetic and
antigenic characteristics of the agents; (8) develops, evaluates, and
improves diagnostic methods and reagents, and transfers assays and
techniques to other public health laboratories; (9) facilitates and
participates in the development and evaluation of antiviral compounds,
vaccines, and vaccination programs; (10) provides and supports public
health training; (11) responds to and assists internal and external
partners on other public health problems of national and international
significance, as needed; (12) provides technical support to state
immunization programs for all aspects of vaccine-preventable diseases
and their vaccines; (13) provides leadership in vaccine science; and
(14) supports CDC's Immunization Safety Office in vaccine safety risk
assessment and leadership in vaccine safety risk management.
Office of the Director (CVGE1). (1) Manages, directs, and
coordinates the activities of the division; (2) provides leadership and
guidance in policy formulation, program planning and development,
program management, and operations of the division; (3) identifies
needs and resources for ongoing and new initiatives and assigns
responsibilities for their development; (4) prepares, reviews, and
coordinates informational, scientific, and programmatic documents; (5)
oversees the division's activities and expenditures; (6) assures the
overall quality of the science conducted by the division; (7) provides
overall guidance and direction for the division's surveillance,
research, and other scientific and immunization activities; (8)
provides overall guidance and direction for division's epidemiologic,
laboratory, and outbreak response capacity and activities; (9) oversees
and facilitates the division's scientific support to other groups
within CDC, the national and international healthcare, and public
health communities regarding viral respiratory and enteric diseases and
viral immunization programs; (10) guides and facilitates efficient
coordination and cooperation for administrative, programmatic, and
scientific activities within the division and with other groups inside
and outside of CDC; and (11) provides division leadership, expertise,
and technical collaboration for the application of statistics,
economics, operations research, geography, other quantitative sciences,
and data management to prevent disease, disability and death through
immunization and control of respiratory, enteric, and related viral
diseases.
Analysis and Data Management Activity (CVGE12). (1) Coordinates
quantitative science and data management planning, policy development,
and project monitoring and evaluation; (2) designs and develops
statistical, economic, cost, resource allocation, geospatial and data
management strategies, models, and methodologies in the public health
arena; and (3) collaborates with scientists, program experts, and
senior public health officials throughout the division to implement
these strategies, models, and methodologies in support of respiratory,
enteric and related viral diseases surveillance and prevention studies,
prevention resource allocation issues, and prevention program
activities.
Respiratory Viruses Branch (CVGEB). (1) Conducts surveillance,
laboratory assistance, and related activities, and supports and
provides technical assistance to state and local health departments to
conduct surveillance and related activities to monitor the impact of
prevention programs, and determine patterns of infection and disease;
(2) conducts and provides laboratory support and expertise for
epidemiologic and laboratory studies to define patterns of and risk
factors for infection, disease, and disease burden; (3) provides
epidemiology and laboratory consultation and support and/or
participates in investigations of national and international outbreaks
of viral respiratory diseases, and recommends appropriate control
measures; (4) provides scientific, both epidemiologic and laboratory,
leadership and advice; (5) analyzes available data, and develops
science-based statements for potential respiratory viral vaccines to
the ACIP and other groups to support the development and evaluation of
immunization practices and policies in the U.S and internationally; (6)
provides and supports public health training; (7) responds to and
assists internal and
[[Page 57456]]
external partners on other public health problems of national and
international significance, as needed; (8) provides laboratory support
for surveillance and epidemiologic studies and maintains reference/
diagnostic services and expertise; (9) conducts studies of immunology
and pathogenesis of disease and the biology, biochemical, genetic, and
antigenic characteristics of the agents; (10) develops, evaluates, and
improves diagnostic methods and reagents, and transfers assays and
techniques to other public health laboratories and provides and
supports laboratory training; (11) facilitates and participates in the
development and evaluation of antiviral compounds, vaccines, and
vaccination programs; and (12) responds to and assists internal and
external partners on other public health problems of national and
international significance as needed.
Polio and Picornavirus Laboratory Branch (CVGEC). (1) Provides
laboratory assistance, technical expertise and support for surveillance
and related activities to monitor impact of vaccination and other
prevention programs, and determine patterns of infection and disease;
(2) provides laboratory support and technical expertise for
epidemiologic and laboratory studies to define patterns and risk
factors for infection, disease, and disease burden; (3) studies
vaccine-related issues; (4) identifies and evaluate non-vaccine
prevention strategies; (5) provides laboratory consultation and
technical expertise regarding use of vaccines and other measures to
prevent infections to other NCs, collaborators, and partners; (6)
provides laboratory consultation and support and/or participates in
investigations of national and international outbreaks of viral vaccine
preventable and other respiratory and enteric viral diseases; (7)
provides laboratory leadership and technical expertise to develop
science-based statements to Global Polio Eradication Initiative, the
ACIP, and other groups to support the development and evaluation of
immunization practices and policies in the U.S and internationally; (8)
provides epidemiology and laboratory consultation and support and/or
participates in investigations of national and international outbreaks
of viral respiratory diseases, and recommends appropriate control
measures; (9) provides scientific, both epidemiologic and laboratory,
leadership and advice; (10) provides laboratory support for
surveillance and epidemiologic studies and maintains reference/
diagnostic services and expertise; (11) conducts studies of immunology
and pathogenesis of disease and the biology, biochemical, genetic, and
antigenic characteristics of the agents; (12) develops, evaluates, and
improves diagnostic methods and reagents, transfers assays and
techniques to national and international public health laboratories,
and provides and supports training for laboratorians; (13) facilitates
and participates in the development and evaluation of antiviral
compounds, vaccines, and vaccination programs; (14) responds to and
assists internal and external partners on other public health problems
of national and international significance as needed; and (15) serves
as the National Reference Laboratory (poliovirus and enteroviruses),
World Health Organization (WHO) Collaborating Center for Poliovirus and
Enteroviruses Virus Reference and Research, and WHO Global Specialized
Polio Reference Laboratory.
Viral Vaccine Preventable Diseases Branch (CVGED). (1) Conducts
surveillance, provides laboratory assistance, technical expertise, and
support for surveillance and related activities to monitor the impact
of vaccination on the prevention of viral disease and to determine
patterns of infection and disease; (2) conducts epidemiologic and
laboratory studies to define patterns of and risk factors for
infection, disease, and disease burden; (3) estimates vaccine
effectiveness, evaluates other aspects of immunization practices; (4)
identifies and evaluates non-vaccine prevention strategies; (5)
provides epidemiological and laboratory expertise and technical support
to other NCs, collaborators, and partners across center working groups
on vaccines and other prevention strategies; (6) supports the
development of vaccine practices and policies by providing consultation
and epidemiologic and laboratory expertise to other federal agencies,
state health departments, ministries of health, WHO, PAHO, private
industry, academia and other governmental organizations on viral
vaccine preventable diseases, and on the use of vaccines and other
measures to prevent infections; (7) provides laboratory consultation
and support and/or participates in investigations of national and
international outbreaks of viral vaccine preventable diseases and
recommends appropriate control measures; (8) assists internal and
external partners on other public health problems of national and
international significance; (9) provides scientific leadership and
advice, analyzes available data, and develops science-based statements
for viral vaccines to the ACIP and other groups to support the
development and evaluation of immunization practices and policies in
the U.S and internationally; (10) responsible for human papilloma virus
(HPV), measles, mumps, rubella (MMR), domestic polio, zoster, and
varicella vaccine policy in the United States by working with ACIP;
(11) provides and supports public health training; (12) responds to
public inquires and prepares communication materials; (13) works with
health economists to determine cost effectiveness of vaccination
strategies; (14) provides laboratory support for surveillance and
epidemiologic studies and maintains reference and diagnostic services
and expertise; (15) assists in investigation of adverse events
following vaccination; (16) conducts studies of immunology and
pathogenesis of disease and the biological, biochemical, genetic, and
antigenic characteristics of viral agents; (17) develops, evaluates,
and improves diagnostic methods and reagents; (17) transfers assays and
techniques to other public health laboratories; (18) provides and
supports laboratory training; (19) serves as the National Reference
Laboratory for MMR, and varicella zoster virus and the PAHO Regional
and WHO Global Specialized Laboratory for measles and rubella; and (20)
works closely with the laboratory that handles HPV to define and
conduct epidemiologic investigations.
Viral Gastroenteritis Branch (CVGEE) (1) Provides epidemiologic and
laboratory assistance studies and related activities to better
understand the evolution, (molecular) epidemiology and immunity of
rotavirus, norovirus and other gastroenteritis viruses; (2) provides
consultation on the safety and impact of rotavirus vaccination and
other prevention programs (rotavirus, norovirus); (3) provides
consultation and technical assistance to state and local health
departments to monitor the burden of disease and epidemiology of
gastroenteritis virus infections (rotavirus, norovirus); (4) provides
consultation and support on the research and development of new
rotavirus vaccines and other prevention technologies; (5) provides
consultation and support and/or participates in investigations of
national and international outbreaks of viral vaccine preventable and
other enteric viral diseases, and recommends appropriate control
measures; (6) provides scientific leadership and advice, analyzes
available data, and develops science-based statements for rotavirus
vaccines to the ACIP and other groups to support the development and
evaluation of
[[Page 57457]]
immunization practices and policies in the U.S and internationally; (7)
provides and supports public health training; (8) responds to and
assists internal and external partners on other public health problems
of national and international significance, as needed; (9) serves as
the National Reference Laboratory (rotavirus and norovirus) and other
agents of viral gastroenteritis; and (10) serves as the WHO Global
Reference Center for Rotavirus and other agents of viral
gastroenteritis.
Sherri Berger,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2017-26150 Filed 12-4-17; 8:45 am]
BILLING CODE 4160-18-P
